We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals

357 hedge funds and large institutions have $8.94B invested in Jazz Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 126 increasing their positions, 120 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 36

25% more funds holding in top 10

Funds holding in top 10: 1215 (+3)

10% more funds holding

Funds holding: 325357 (+32)

5% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 120

4% more capital invested

Capital invested by funds: $8.58B → $8.94B (+$355M)

27% less call options, than puts

Call options by funds: $86.4M | Put options by funds: $119M

Holders
357
Holders Change
+32
Holders Change %
+9.85%
% of All Funds
9.52%
Holding in Top 10
15
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+25%
% of All Funds
0.4%
New
76
Increased
126
Reduced
120
Closed
36
Calls
$86.4M
Puts
$119M
Net Calls
-$32.4M
Net Calls Change
+$92.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Swiss National Bank
101
Swiss National Bank
Switzerland
$9.12M -$232K -1,400 -2%
Susquehanna International Group
102
Susquehanna International Group
Pennsylvania
$8.48M -$1.08M -6,527 -11%
NC
103
Nicholas Company
Wisconsin
$7.87M
State of Wisconsin Investment Board
104
State of Wisconsin Investment Board
Wisconsin
$7.59M +$440K +2,650 +6%
Goldman Sachs
105
Goldman Sachs
New York
$7.57M -$51.6K -311 -0.7%
BA
106
Boston Advisors
Massachusetts
$7.41M +$1.45M +8,735 +24%
RhumbLine Advisers
107
RhumbLine Advisers
Massachusetts
$7.24M -$194K -1,170 -3%
RFC
108
Russell Frank Company
Washington
$7.22M -$1.38M -8,298 -16%
ProShare Advisors
109
ProShare Advisors
Maryland
$7.09M +$1.66M +10,023 +30%
TI
110
Turner Investments
Pennsylvania
$6.91M -$4.91M -29,563 -41%
DekaBank Deutsche Girozentrale
111
DekaBank Deutsche Girozentrale
Germany
$6.64M +$553K +3,330 +9%
CIBC Private Wealth Group
112
CIBC Private Wealth Group
Georgia
$6.17M +$7.3K +44 +0.1%
CAM
113
CG Asset Management
New York
$6.14M +$93.8K +565 +2%
AAM
114
Advisors Asset Management
Colorado
$5.86M +$225K +1,358 +4%
BIM
115
BlackRock Investment Management
Delaware
$5.5M +$1.08M +6,491 +24%
Bank of Montreal
116
Bank of Montreal
Ontario, Canada
$5.48M -$381K -2,295 -6%
SB
117
Suntrust Banks
Georgia
$5.4M -$867K -5,226 -14%
Fiera Capital (Canada)
118
Fiera Capital (Canada)
Quebec, Canada
$5.29M -$1.88M -11,300 -26%
OAM
119
Oxford Asset Management
United Kingdom
$5.04M +$2.76M +16,648 +123%
AWCI
120
Alpine Woods Capital Investors
New York
$5.02M +$78K +470 +2%
Korea Investment Corp
121
Korea Investment Corp
South Korea
$5.01M +$5.08M +30,600 New
NIP
122
Nicholas Investment Partners
California
$4.97M +$4.81K +29 +0.1%
QGM
123
Quality Growth Management
California
$4.93M -$1.18M -7,080 -19%
PRCM
124
Pine River Capital Management
Minnesota
$4.91M +$4.98M +30,000 New
JAM
125
JW Asset Management
Florida
$4.68M +$4.75M +28,617 New

JAZZ Hedge Fund Activity: Q4 2014 in Review

357 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2014, worth a combined $8.94B — up 4.1% from $8.58B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new JAZZ positions and 36 closed out — a net gain of 40 holders — while 126 added to existing stakes and 120 trimmed.

The largest buyer was American Century Companies, adding an estimated $71.4M. The largest seller was Wells Fargo, cutting an estimated $119M.

  • 357 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2014, up from 325 in Q3 2014.
  • Funds reported $8.94B of Jazz Pharmaceuticals stock for Q4 2014, up 4.1% quarter-over-quarter.
  • 76 funds opened new Jazz Pharmaceuticals positions in Q4 2014 and 36 closed out, a net change of +40 holders.
  • The largest Jazz Pharmaceuticals buyer in Q4 2014 was American Century Companies, an estimated $71.4M added.
  • The largest Jazz Pharmaceuticals seller in Q4 2014 was Wells Fargo, an estimated $119M sold.

Based on aggregated 13F filings for Q4 2014.